<DOC>
	<DOCNO>NCT01559363</DOCNO>
	<brief_summary>The primary objective study determine safety , plasma pharmacokinetics , maximum tolerate dose ( MTD ) KD019 administer subject ADPKD .</brief_summary>
	<brief_title>A Safety , Pharmacokinetic Dose-Escalation Study KD019 Subjects With Autosomal Dominant Polycystic Kidney Disease ( ADPKD )</brief_title>
	<detailed_description>Phase 1 : - Primary purpose determine safety KD019 . - Dosing 28 day daily . After 28-day treatment period , subject , discretion investigator , continue receive study treatment 24 month first dose development unacceptable toxicity , noncompliance , withdrawal consent subject , investigator decision . Subjects may continue beyond 24 month discretion investigator consultation medical monitor . - All participant receive active KD019 study drug . - KD019 oral daily tablet . Tablets 50 mg , 100 mg 150 mg strength . Participants enroll three sequential dose cohort level ( 50 mg , 100 mg 150 mg. ) . Participants Phase 1b dose increase decreased MTD . - Study participant MRI abdomen ( kidney ) Screening 6 month thereafter explore effect KD019 . - Echocardiogram perform Screening , Day 28 , month 3 6 every 6 month thereafter . Phase 2 : - Primary purpose compare annualized change glomerular filtration rate ( GFR ) subject ADPKD treat KD019 . - Two alternate dose schedule explore determine tolerable daily dose use chronically subject ADPKD . - Subjects receive study treatment 24 month first dose development unacceptable toxicity , noncompliance , withdrawal consent subject , investigator decision . Subjects may continue beyond 24 month discretion investigator consultation sponsor . - All participant receive active KD019 study drug . - Tablets 50 mg , 100 mg , 150 mg strength . - Study participant MRI abdomen ( kidney ) Screening Month 6 visit every 6 month explore effect KD019 . - Echocardiogram perform Screening , Day 28 , Months 3 6 6 month thereafter .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Polycystic Kidney Diseases</mesh_term>
	<mesh_term>Polycystic Kidney , Autosomal Dominant</mesh_term>
	<criteria>The subject confirm diagnosis ADPKD . The subject GFR ≥ 35 mL/min/1.73 m2 . Cysts must least 1 cm size . Adequate bone marrow , kidney , liver function . Must agree use two form birth control child bear potential Normal amylase lipase level The subject htTKV ≥ 1000 mL The subject previous partial total nephrectomy . The subject tuberous sclerosis , HippelLindau disease , acquire cystic disease . The subject congenital absence one kidney and/or need dialysis . Presence renal hepatic calculus ( stone ) cause symptom . The subject receive investigational therapy within 30 day prior study entry . Active treatment ( within 4 week study entry ) urinary tract infection . Subject know immunocompromised Subject pregnant nursing History pericardial effusion presence pericardial effusion screen echocardiogram Uncontrolled hypertension History pancreatitis know risk factor pancreatitis Subject receive EGFR inhibitor time The subject aphakic due previous cataract surgery congenital anomaly</criteria>
	<gender>All</gender>
	<minimum_age>22 Years</minimum_age>
	<maximum_age>62 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>